This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human VEGF-B Protein, His Tag
catalog :
VE6-H5225
quantity :
50 ug, 20 ug
price :
350 USD, 180 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
VE6-H5225
product name :
Human VEGF-B Protein, His Tag
quantity :
50 ug, 20 ug
price :
350 USD, 180 USD
quantity & price :
$180/20ug,$350/50ug
target :
VEGF-B
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human VEGF-B, His Tag (VE6-H5225) is expressed from human 293 cells (HEK293). It contains AA Pro 22 - Ala 207 (Accession # P49765-1).
SDS-PAGE Remark(R&NR) :
Human VEGF-B, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than .
Formulation :
Please contact us for detailed information. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Vascular endothelial growth factor B (VEGFB) is also known as VEGF-related factor (VRF), is a secreted O-glycosylated protein, which belongs to the PDGF/VEGF growth factor family. VEGFB is expressed in all tissues except liver. Highest levels found in heart, skeletal muscle and pancreas. VEGFB is growth factor for endothelial cells. VEGF-B seems to play a role only in the maintenance of newly formed blood vessels during pathological conditions. VEGF-B also plays an important role on several types of neurons. It is important for the protection of neurons in the retina and the cerebral cortex during stroke and of motoneurons during motor neuron diseases such as amyotrophic lateral sclerosis.VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis.
References :
(1) Olofsson B., et al., 1996, Proc. Natl. Acad. Sci. U.S.A. 93:2576-2581.
(2) Iyer S., et al., 2006, J. Mol. Biol. 359:76-85.
(3) Zhang F., et al., 2009, Proc. Natl. Acad. Sci. U.S.A. 106 (15): 6152–7.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments